ASCO Voice of China | Prof. Yinying Wu Reviews Advances in Gastrointestinal Oncology: RAS-Targeted Therapy Reaches a Milestone as Multiple Chinese Original Studies Take Center Stage

ASCO Voice of China | Prof. Yinying Wu Reviews Advances in Gastrointestinal Oncology: RAS-Targeted Therapy Reaches a Milestone as Multiple Chinese Original Studies Take Center Stage

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in grand fashion in Chicago, showcasing numerous highlights and breakthroughs in gastrointestinal oncology. On this occasion, Oncology Frontier invited Prof. Yinying Wu from the First Affiliated Hospital of Xi’an Jiaotong University to share her perspectives and discuss the impressive contributions of Chinese investigator-initiated research presented at this year’s meeting.
CGOG 2026 Day 4 | Precision Translational Medicine Forum

CGOG 2026 Day 4 | Precision Translational Medicine Forum

Following the successful online sessions held during the first three days of the CGOG Annual Meeting, including six ASCO Highlights sessions and six thematic symposia, the on-site program officially commenced on June 12. On Day 4 of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting, two parallel forums attracted strong interest from attendees. The Precision Translational Medicine Forum brought together experts from a wide range of academic disciplines for in-depth exchange and discussion.
“Addition and Subtraction” in the Era of Precision Chemotherapy: Optimization Pathways for High-Risk HR+/HER2- Breast Cancer Chemotherapy Strategies Based on the WSG Pooled Analysis

“Addition and Subtraction” in the Era of Precision Chemotherapy: Optimization Pathways for High-Risk HR+/HER2- Breast Cancer Chemotherapy Strategies Based on the WSG Pooled Analysis

In the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, the choice of chemotherapy regimen, timing of administration (neoadjuvant vs. adjuvant), and optimization of dose density remain focal points of clinical debate for biologically high-risk patients. In a recent academic conference, Professor Oleg Gluz from the West German Study Group (WSG) shared pooled analysis data from the WSG ADAPT-HR+/HER2- and PlanB studies. This analysis focused on a high-risk population with a Recurrence Score (RS) >25 or lymph node positivity (>4), aiming to explore the impact of different chemotherapy strategies on long-term patient survival.
A New Breakthrough in Adjuvant Endocrine Therapy: lidERA Study Confirms Giredestrant Significantly Improves iDFS in Pre/Postmenopausal HR+ Early Breast Cancer

A New Breakthrough in Adjuvant Endocrine Therapy: lidERA Study Confirms Giredestrant Significantly Improves iDFS in Pre/Postmenopausal HR+ Early Breast Cancer

At the recent 2026 ASCO Annual Meeting, Professor Peter Schmid, representing the lidERA study group from the Barts Cancer Institute, Queen Mary University of London, detailed the efficacy and safety analysis results based on menopausal status (pre/perimenopausal vs. postmenopausal) from the Phase III lidERA BC clinical trial. The study aims to evaluate the clinical value of Giredestrant (GIRE), a next-generation oral selective estrogen receptor degrader (SERD), in the adjuvant treatment of patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) early breast cancer (eBC).
Regardless of Trop-2, BRCA, or HER2 Status, SG plus Pembrolizumab Significantly Improves PFS in 1L PD-L1+ mTNBC Patients: Subgroup Analysis of the ASCENT-04 Study

Regardless of Trop-2, BRCA, or HER2 Status, SG plus Pembrolizumab Significantly Improves PFS in 1L PD-L1+ mTNBC Patients: Subgroup Analysis of the ASCENT-04 Study

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Sara M. Tolaney from Dana-Farber Cancer Institute and Harvard Medical School, representing the research team, presented the latest exploratory analysis results of the ASCENT-04 study (NCT04612127). This analysis delved into the impact of biomarkers—Trop-2 expression levels, BRCA mutation status, and HER2 expression status—on the efficacy of Sacituzumab Govitecan (SG) combined with Pembrolizumab as a first-line treatment for PD-L1 positive metastatic triple-negative breast cancer (mTNBC), providing key evidence for the precise selection of benefited populations in clinical practice.
Balancing QoL Improvement Against Implant Risk: The Phase III Randomized PREPEC Trial Reveals Short- and Long-Term Benefits of Prepectoral Breast Reconstruction

Balancing QoL Improvement Against Implant Risk: The Phase III Randomized PREPEC Trial Reveals Short- and Long-Term Benefits of Prepectoral Breast Reconstruction

At a recent international academic conference, Professor Walter Weber from University Hospital Basel, Switzerland, detailed the results of the international randomized Phase III PREPEC trial (OPBC-02). The study aimed to compare the impact of two implant placement strategies—Prepectoral versus traditional Subpectoral—on the quality of life and safety of patients undergoing implant-based breast reconstruction (IBBR) following therapeutic or prophylactic mastectomy.